Literature DB >> 27259398

Delivery strategies and potential targets for siRNA in major cancer types.

So Jin Lee1,2, Min Ju Kim1,2,3, Ick Chan Kwon2,3, Thomas M Roberts1.   

Abstract

Small interfering RNA (siRNA) has gained attention as a potential therapeutic reagent due to its ability to inhibit specific genes in many genetic diseases. For many years, studies of siRNA have progressively advanced toward novel treatment strategies against cancer. Cancer is caused by various mutations in hundreds of genes including both proto-oncogenes and tumor suppressor genes. In order to develop siRNAs as therapeutic agents for cancer treatment, delivery strategies for siRNA must be carefully designed and potential gene targets carefully selected for optimal anti-cancer effects. In this review, various modifications and delivery strategies for siRNA delivery are discussed. In addition, we present current thinking on target gene selection in major tumor types.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Delivery strategy of siRNAs; Gene target; Small interfering RNA (siRNA); siRNA therapeutics

Mesh：

Substances：

Year:  2016        PMID： 27259398      PMCID： PMC4958528          DOI： 10.1016/j.addr.2016.05.010

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN： 0169-409X            Impact factor:   15.470


  217 in total

1.  RNA interference in mammalian cells by chemically-modified RNA.

Authors:  Dwaine A Braasch; Susan Jensen; Yinghui Liu; Kiran Kaur; Khalil Arar; Michael A White; David R Corey
Journal:  Biochemistry       Date:  2003-07-08       Impact factor: 3.162

Review 2.  DNA methylation and gene silencing in cancer.

Authors:  Stephen B Baylin
Journal:  Nat Clin Pract Oncol       Date:  2005-12

3.  Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors:  James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2006-06-25       Impact factor: 54.908

Review 4.  Recent progress in copolymer-mediated siRNA delivery.

Authors:  Zong-Wei Wu; Chih-Te Chien; Chia-Yeh Liu; Jia-Ying Yan; Shu-Yi Lin
Journal:  J Drug Target       Date:  2012-08       Impact factor: 5.121

Review 5.  Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer.

Authors:  Meysam Abbasi; Afsaneh Lavasanifar; Hasan Uludag
Journal:  Med Res Rev       Date:  2011-04-26       Impact factor: 12.944

6.  Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology.

Authors:  Chun-Fang Xia; Yufeng Zhang; Yun Zhang; Ruben J Boado; William M Pardridge
Journal:  Pharm Res       Date:  2007-10-11       Impact factor: 4.200

Review 7.  Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.

Authors:  Ana Bosch; Pilar Eroles; Rosa Zaragoza; Juan R Viña; Ana Lluch
Journal:  Cancer Treat Rev       Date:  2010-01-08       Impact factor: 12.111

8.  Combination of dendrimer-nanovector-mediated small interfering RNA delivery to target Akt with the clinical anticancer drug paclitaxel for effective and potent anticancer activity in treating ovarian cancer.

Authors:  Shashwati Kala; Abby Sin Chi Mak; Xiaoxuan Liu; Paola Posocco; Sabrina Pricl; Ling Peng; Alice Sze Tsai Wong
Journal:  J Med Chem       Date:  2014-03-18       Impact factor: 7.446

9.  Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug.

Authors:  Vatsal Shah; Oleh Taratula; Olga B Garbuzenko; Olena R Taratula; Lorna Rodriguez-Rodriguez; Tamara Minko
Journal:  Clin Cancer Res       Date:  2013-09-13       Impact factor: 12.531

Review 10.  Interfering with disease: a progress report on siRNA-based therapeutics.

Authors:  Antonin de Fougerolles; Hans-Peter Vornlocher; John Maraganore; Judy Lieberman
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694
View more
  28 in total

1.  Exploring the HYDRAtion method for loading siRNA on liposomes: the interplay between stability and biological activity in human undiluted ascites fluid.

Authors:  George R Dakwar; Kevin Braeckmans; Wim Ceelen; Stefaan C De Smedt; Katrien Remaut
Journal:  Drug Deliv Transl Res       Date:  2017-04       Impact factor: 4.617

Review 2.  Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs.

Authors:  Fang Liu; Chunfang Wang; Yuantao Gao; Xiao Li; Feng Tian; Yongtao Zhang; Mingyang Fu; Pengfei Li; Yali Wang; Fei Wang
Journal:  Mol Diagn Ther       Date:  2018-10       Impact factor: 4.074

3.  Effectiveness of Small Interfering RNA Delivery via Arginine-Rich Polyethylenimine-Based Polyplex in Metastatic and Doxorubicin-Resistant Breast Cancer Cells.

Authors:  Shan Lu; Viola B Morris; Vinod Labhasetwar
Journal:  J Pharmacol Exp Ther       Date:  2019-04-02       Impact factor: 4.030

4.  Polymer nanoassemblies with hydrophobic pendant groups in the core induce false positive siRNA transfection in luciferase reporter assays.

Authors:  Steven Rheiner; Derek Reichel; Piotr Rychahou; Tadahide Izumi; Hsin-Sheng Yang; Younsoo Bae
Journal:  Int J Pharm       Date:  2017-06-16       Impact factor: 5.875

5.  Supportive Oligonucleotide Therapy (SOT) as an Alternative Treatment Option in Cancer: A Preliminary Study.

Authors:  Ioannis Papasotiriou; Georgios Beis; Aggelos C Iliopoulos; Panagiotis Apostolou
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

6.  CD73 downregulation by EGFR-targeted liposomal CD73 siRNA potentiates antitumor effect of liposomal doxorubicin in 4T1 tumor-bearing mice.

Authors:  Anvar Soleimani; Farshad Mirzavi; Sara Nikoofal-Sahlabadi; Amin Reza Nikpoor; Bita Taghizadeh; Mehdi Barati; Mohammad Soukhtanloo; Mahmoud Reza Jaafari
Journal:  Sci Rep       Date:  2022-06-21       Impact factor: 4.996

7.  LentiRILES, a miRNA-ON sensor system for monitoring the functionality of miRNA in cancer biology and therapy.

Authors:  Viorel Simion; Claire Loussouarn; Yoan Laurent; Loris Roncali; David Gosset; Flora Reverchon; Audrey Rousseau; Francisco Martin; Patrick Midoux; Chantal Pichon; Emmanuel Garcion; Patrick Baril
Journal:  RNA Biol       Date:  2021-09-27       Impact factor: 4.766

8.  Engineered exosome-mediated delivery of functionally active miR-26a and its enhanced suppression effect in HepG2 cells.

Authors:  Gaofeng Liang; Shu Kan; Yanliang Zhu; Shuying Feng; Wenpo Feng; Shegan Gao
Journal:  Int J Nanomedicine       Date:  2018-01-30

9.  Dual Tumor-Targeting Nanocarrier System for siRNA Delivery Based on pRNA and Modified Chitosan.

Authors:  Lin Li; Xiaoqin Hu; Min Zhang; Siyu Ma; Fanglin Yu; Shiqing Zhao; Nan Liu; Zhiyuan Wang; Yu Wang; Hua Guan; Xiujie Pan; Yue Gao; Yue Zhang; Yan Liu; Yang Yang; Xuemei Tang; Mingyuan Li; Cheng Liu; Zhiping Li; Xingguo Mei
Journal:  Mol Ther Nucleic Acids       Date:  2017-06-21       Impact factor: 8.886

10.  Synthesis and evaluation of L-arabinose-based cationic glycolipids as effective vectors for pDNA and siRNA in vitro.

Authors:  Bo Li; Wanrong Guo; Fan Zhang; Meiyan Liu; Shang Wang; Zhonghua Liu; Shuanglin Xiang; Youlin Zeng
Journal:  PLoS One       Date:  2017-07-03       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.